NVCT

+ Watchlist + Portfolio

Nuvectis Pharma, Inc.

GridBrain — Sign in

GridSentinel — Sign in

GridAegis — Sign in

Key Metrics

Previous Close: $23.33
52-Week Range: $5.55 – $29.28
Market Cap: $760.78M
P/E (TTM): —
EPS (TTM): -1.32
Dividend Yield: —

Advanced Metrics

Price/Book: 68.68
PEG Ratio: —
Return on Equity: -214.58%
Return on Assets: -73.07%
Gross Margin: 0.00%
Operating Margin: 0.00%
Profit Margin: 0.00%
Current Ratio: 1.68
Debt/Equity: —
Total Debt: $0.00
Free Cash Flow: $-8.89M
Revenue Growth: —
Earnings Growth: —
Enterprise Value: $738.62M

NVCT Income statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Revenue	$0.00	$0.00	$0.00	$0.00
Research & Development	$13.23M	$15.38M	$12.92M	$18.15M
Selling, General & Admin	$6.01M	$7.52M	$6.93M	$9.42M
Operating Expenses	$19.23M	$22.90M	$19.85M	$27.57M
Operating Income	-$19.23M	-$22.90M	-$19.85M	-$27.57M
EBITDA	-$19.23M	-$22.90M	-$19.85M	-$27.57M
Pretax Income	-$19.09M	-$22.26M	-$19.00M	-$26.44M
Net Income	-$19.09M	-$22.26M	-$19.00M	-$26.44M
Diluted EPS	-1.51	-1.43	-1.11	-1.32
Diluted Shares	12.66M	15.56M	17.11M	21.81M

NVCT Balance Sheet statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Cash & Equivalents	$19.99M	$19.13M	$18.53M	$31.63M
Current Assets	$20.41M	$19.18M	$18.61M	$31.71M
Total Assets	$20.41M	$19.18M	$18.61M	$31.71M
Current Liabilities	$6.19M	$6.98M	$8.89M	$13.30M
Total Liabilities	$6.19M	$6.98M	$8.89M	$13.30M
Retained Earnings	-$31.98M	-$54.24M	-$73.25M	-$99.69M
Shareholders' Equity	$14.22M	$12.20M	$9.71M	$18.41M
Working Capital	$14.22M	$12.20M	$9.71M	$18.41M

NVCT Cash Flow statement, annual periods, in USD
USD	FY2022	FY2023	FY2024	FY2025
Operating Cash Flow	-$13.56M	-$15.95M	-$12.25M	-$16.01M
Free Cash Flow	-$13.56M	-$15.95M	-$12.25M	-$16.01M
Stock-Based Compensation	$1.71M	$4.71M	$4.86M	$6.03M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$27.81M	$15.09M	$11.65M	$29.11M
Net Change in Cash	$14.25M	-$867.00K	-$593.00K	$13.10M

NVCT Income statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Research & Development	$3.68M	$3.61M	$5.77M	$5.09M	$4.11M
Selling, General & Admin	$1.89M	$2.98M	$2.02M	$2.53M	$2.15M
Operating Expenses	$5.57M	$6.59M	$7.79M	$7.62M	$6.26M
Operating Income	-$5.57M	-$6.59M	-$7.79M	-$7.62M	-$6.26M
EBITDA	-$5.57M	-$6.59M	-$7.79M	-$7.62M	-$6.26M
Pretax Income	-$5.33M	-$6.33M	-$7.46M	-$7.31M	-$6.05M
Net Income	-$5.33M	-$6.33M	-$7.46M	-$7.31M	-$6.05M
Diluted EPS	-0.27	-0.30	-0.44	—	-0.26
Diluted Shares	19.94M	21.37M	22.72M	—	23.41M

NVCT Balance Sheet statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Cash & Equivalents	$29.86M	$26.79M	$35.44M	$31.63M	$25.13M
Current Assets	$30.15M	$27.01M	$35.59M	$31.71M	$25.40M
Total Assets	$30.15M	$27.01M	$35.59M	$31.71M	$25.40M
Current Liabilities	$9.19M	$10.13M	$11.58M	$13.30M	$11.18M
Total Liabilities	$9.19M	$10.13M	$11.58M	$13.30M	$11.18M
Retained Earnings	-$78.58M	-$84.91M	-$92.37M	-$99.69M	-$105.74M
Shareholders' Equity	$20.95M	$16.87M	$24.01M	$18.41M	$14.22M
Working Capital	$20.95M	$16.87M	$24.01M	$18.41M	$14.22M

NVCT Cash Flow statement, quarterly periods, in USD
USD	Q1 2025	Q2 2025	Q3 2025	Q4 2025	Q1 2026
Operating Cash Flow	-$4.17M	-$3.37M	-$4.49M	-$3.97M	-$6.51M
Free Cash Flow	-$4.17M	-$3.37M	-$4.49M	-$3.97M	-$6.51M
Stock-Based Compensation	$1.37M	$1.73M	$1.46M	$1.48M	$1.85M
Investing Cash Flow	$0.00	$0.00	$0.00	$0.00	$0.00
Financing Cash Flow	$15.51M	$296.00K	$13.14M	$166.00K	$7.00K
Net Change in Cash	$11.33M	-$3.07M	$8.65M	-$3.81M	-$6.50M

Market Snapshot

About

Nuvectis Pharma, Inc. is a biopharmaceutical company focused on precision oncology through the development of innovative treatments for serious unmet medical needs in cancer. The company targets specific cancer vulnerabilities with therapies designed to selectively kill tumor cells while sparing healthy tissue. Nuvectis combines novel drug candidates with companion diagnostics to identify patients most likely to benefit.